These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia. Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB Clin Cancer Res; 2015 Mar; 21(6):1395-405. PubMed ID: 25573381 [TBL] [Abstract][Full Text] [Related]
15. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia. Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323 [TBL] [Abstract][Full Text] [Related]
16. Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements. Wen J; Zhou M; Shen Y; Long Y; Guo Y; Song L; Xiao J BMC Cancer; 2022 Aug; 22(1):859. PubMed ID: 35933338 [TBL] [Abstract][Full Text] [Related]
17. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. Urtishak KA; Wang LS; Culjkovic-Kraljacic B; Davenport JW; Porazzi P; Vincent TL; Teachey DT; Tasian SK; Moore JS; Seif AE; Jin S; Barrett JS; Robinson BW; Chen IL; Harvey RC; Carroll MP; Carroll AJ; Heerema NA; Devidas M; Dreyer ZE; Hilden JM; Hunger SP; Willman CL; Borden KLB; Felix CA Oncogene; 2019 Mar; 38(13):2241-2262. PubMed ID: 30478448 [TBL] [Abstract][Full Text] [Related]
18. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. Pieters R; De Lorenzo P; Ancliffe P; Aversa LA; Brethon B; Biondi A; Campbell M; Escherich G; Ferster A; Gardner RA; Kotecha RS; Lausen B; Li CK; Locatelli F; Attarbaschi A; Peters C; Rubnitz JE; Silverman LB; Stary J; Szczepanski T; Vora A; Schrappe M; Valsecchi MG J Clin Oncol; 2019 Sep; 37(25):2246-2256. PubMed ID: 31283407 [TBL] [Abstract][Full Text] [Related]
19. Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1. Guest EM; Kairalla JA; Devidas M; Hibbitts E; Carroll AJ; Heerema NA; Kubaney HR; August MA; Ramesh S; Yoo B; Farooqi MS; Pauly MG; Wechsler DS; Miles RR; Reid JM; Kihei CD; Gore L; Raetz EA; Hunger SP; Loh ML; Brown PA Haematologica; 2024 Jun; ():. PubMed ID: 38867582 [TBL] [Abstract][Full Text] [Related]